| Literature DB >> 18796133 |
Vivek Sagar1, Rajesh Kumar, Nirmal K Ganguly, Anuradha Chakraborti.
Abstract
BACKGROUND: Group A streptococcus (GAS) causes a wide variety of life threatening diseases in humans and the incidence of such infections is high in developing countries like India. Although distribution of emm types of GAS in India has been described, there is a lack of data describing either the comparative distribution of emm types in throat versus skin isolates, or the distribution of certain virulence factors amongst these isolates. Therefore in the present study we have monitored the emm type pattern of Group A streptococcus throat and skin isolates from India. Additionally, the association of these isolates with closely related sic (crs), a multifunctional compliment binding virulence factor, was also explored.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18796133 PMCID: PMC2556678 DOI: 10.1186/1471-2180-8-150
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Distribution of different emm types among throat and skin isolates
| Total Isolates | Throat Isolates | Skin Isolates | |
| 1–2.2 | 6 | 3 | 3 |
| 11.1 | 4 | 3 | 1 |
| 12.13 | 2 | 2 | 0 |
| 18.12 | 2 | 1 | 1 |
| 25.2 | 1 | 1 | 0 |
| 28.5 | 1 | 0 | 1 |
| 33.0 | 1 | 1* | 0 |
| 43.3 | 2 | 2* | 0 |
| 44.0 | 5 | 0 | 5 |
| 49.4 | 8 | 6+1* | 1 |
| 55.0 | 1 | 0 | 1 |
| 67.0 | 1 | 1 | 0 |
| 68.0 | 2 | 2 | 0 |
| 69.1 | 3 | 3 | 0 |
| 70.0 | 1 | 0 | 1 |
| 71.0 | 1 | 0 | 1 |
| 74.0 | 1 | 1 | 0 |
| 75.0 | 6 | 5 | 1 |
| 77.0 | 6 | 4 | 2 |
| 80.0 | 2 | 1* | 1 |
| 81.1 | 3 | 0 | 3 |
| 81.2 | 3 | 1 | 2 |
| 82.1 | 2 | 0 | 2 |
| 86.2 | 1 | 0 | 1 |
| 87.0 | 1 | 1 | 0 |
| 90-2 | 1 | 1 | 0 |
| 92.0 | 1 | 0 | 1 |
| 93.0 | 2 | 2* | 0 |
| 100.1 | 1 | 0 | 1 |
| 102.2 | 1 | 0 | 1 |
| 103.0 | 2 | 0 | 2 |
| 104.0 | 3 | 0 | 3 |
| 106.0 | 1 | 0 | 1 |
| 112.2 | 7 | 1** | 6 |
| 118.0 | 4 | 1 | 3 |
| ST1731.1 | 1 | 0 | 1 |
| ST2861 UK.1 | 1 | 0 | 1 |
| NT | 3 | 1+1* | 1 |
* Represent strains Isolated from RF/RHD patients and ** Chorea patient NT: Represent nontypeable isolate.
Figure 1Characterization of CRS. (A) Screening of crs gene. Lanes: M, 100-bp Ladder (NEB, USA); 1, M1 reference strain used as positive control; 2–7, representative clinical emm1-2 isolates; (-), negative control (without template). B. Multiple sequence analysis of CRS1-2 from representative isolate, SIC1.0 (AP1 strain from Sweden) and CRS57 (reported from Australia). C. Western Blot analysis of CRS. Lanes: 1, M1 reference strain used as positive control; 2, negative control; 3, representative clinical emm1-2 isolate.
Figure 2Genomic location estimation of . (A) 1.2-kb product amplification by primer pair P1 – P2, Lanes: M, 100-bp Ladder (NEB, USA); 1, M1 reference strain used as positive control; 2, representative clinical emm1-2 isolate; 3, sic negative strain; (-), negative control (without template) (B) 2.2-kb product amplification by primer pair P3–P4, Lanes: M, 1-kb Ladder (NEB, USA); 1, M1 reference strain used as positive control; 2, representative clinical emm1-2 isolate; 3, sic negative strain; (-), negative control(without template) (C) 400-bp product amplification by primer pair P5 – P6, Lanes: M, 100-bp Ladder (NEB, USA); 1, M1 reference strain used as positive control; 2, representative clinical emm1-2 isolate; 3, sic negative strain; (-), negative control (without template).
Figure 3. Lanes: M, 1-kb ladder (Invitrogen, USA); 1, M1 reference strain used as positive control; 2–7, representative clinical emm1-2 isolates; (-), negative control(without template).